title: Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects.
abstract: Salt-losing tubulopathies with secondary hyperaldosteronism (SLT) comprise a set of well-defined inherited tubular disorders. Two segments along the distal nephron are primarily involved in the pathogenesis of SLTs: the thick ascending limb of Henle's loop, and the distal convoluted tubule (DCT). The functions of these pre- and postmacula densa segments are quite distinct, and this has a major impact on the clinical presentation of loop and DCT disorders - the Bartter- and Gitelman-like syndromes. Defects in the water-impermeable thick ascending limb, with its greater salt reabsorption capacity, lead to major salt and water losses similar to the effect of loop diuretics. In contrast, defects in the DCT, with its minor capacity of salt reabsorption and its crucial role in fine-tuning of urinary calcium and magnesium excretion, provoke more chronic solute imbalances similar to the effects of chronic treatment with thiazides. The most severe disorder is a combination of a loop and DCT disorder similar to the enhanced diuretic effect of a co-medication of loop diuretics with thiazides. Besides salt and water supplementation, prostaglandin E2-synthase inhibition is the most effective therapeutic option in polyuric loop disorders (e.g., pure furosemide and mixed furosemide-amiloride type), especially in preterm infants with severe volume depletion. In DCT disorders (e.g., pure thiazide and mixed thiazide-furosemide type), renin-angiotensin-aldosterone system (RAAS) blockers might be indicated after salt, potassium, and magnesium supplementation are deemed insufficient. It appears that in most patients with SLT, a combination of solute supplementation with some drug treatment (e.g., indomethacin) is needed for a lifetime.
authors.affiliation: Department of Pediatrics and Adolescent Medicine, Philipps University, Marburg, Germany. seyberth@staff.uni-marburg.de
authors.forename: Hannsjörg W
authors.initials: HW
authors.lastname: Seyberth
authors.forename: Karl P
authors.initials: KP
authors.lastname: Schlingmann
mesh_terms: D000328:Adult; D000450:Aldosterone / Q000494:pharmacology / Q000502:physiology; D001477:Bartter Syndrome / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D005260:Female; D053579:Gitelman Syndrome / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications / Q000473:pathology; D007674:Kidney Diseases / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D007684:Kidney Tubules / Q000473:pathology*; D007686:Kidney Tubules, Distal / Q000473:pathology; D008138:Loop of Henle / Q000378:metabolism / Q000473:pathology; D009399:Nephrons / Q000473:pathology; D011379:Prognosis; D012492:Salts / Q000378:metabolism
chemical_list: D012492:Salts; D000450:Aldosterone